Following Record-breaking IPO, Hepalink's Claims Attract Skepticism
This article was originally published in PharmAsia News
Executive Summary
Following the most expensive IPO to date at RMB 148 per share, Hepalink Pharmaceutical's recent claims of exclusivity for heparin certification have attracted doubt